WO2023016538 - ANTIBODIES SPECIFICALLY RECOGNIZING FCRN AND USES THEREOF
National phase entry:
Publication Number
WO/2023/016538
Publication Date
16.02.2023
International Application No.
PCT/CN2022/111998
International Filing Date
12.08.2022
Title **
[English]
ANTIBODIES SPECIFICALLY RECOGNIZING FCRN AND USES THEREOF
[French]
ANTICORPS RECONNAISSANT SPÉCIFIQUEMENT FCRN ET LEURS UTILISATIONS
Applicants **
STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.
Inventors
ZHANG, Lei
ZHANG, Shuai
HUANG, Jie
LI, Ping
Priority Data
PCT/CN2021/112372
13.08.2021
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2786 | |
| EPO | Filing, Examination, Granting | 19832 | |
| Japan | Filing, Examination, Granting | 2464 | |
| South Korea | Filing, Examination, Granting | 2802 | |
| USA | Filing, Examination, Granting | 9190 |
Total:
37,074
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are antibodies including antigen-binding fragments thereof that specifically recognizing the neonatal Fc receptor (FcRn). Also provided are methods of making and using these antibodies.[French]
L'invention concerne des anticorps, y compris leurs fragments de liaison à l'antigène, qui reconnaissent spécifiquement le récepteur Fc néonatal (FcRn). L'invention concerne également des procédés de fabrication et d'utilisation de ces anticorps.